The first angry calls to the Pretty in Pink Boutique began last August, confusing staff at the Franklin, Tenn., provider of wigs, mastectomy bras and other accessories for cancer patients. Medicare recipients from around the country claimed that a company called Pretty in Pink had charged their health insurance companies thousands of dollars for urinary catheters that they never ordered or received.
Flooded by dozens of complaints, the boutique launched a webpage in September to explain that its leaders were dumbfounded, too.
“We have reported the calls we are receiving to Medicare, and we have been working with callers to try to figure out exactly who is filing these claims,” Pretty in Pink’s website reads, asserting that another company by the same name was submitting the claims, and offering instructions on how to report the fraud to federal officials and insurance companies. “FRAUDULENT CLAIMS ARE BAD FOR ALL OF US, AND WE ARE ON YOUR SIDE.”
The complaints that ensnared the Tennessee cancer-care business are just one piece of an alleged fraud scheme whose scale has little precedent in the history of Medicare, experts said: an estimated $2 billion.
The months-long episode allegedly involves fraudulent insurance claims submitted by seven companies to the taxpayer-funded health insurance program for older Americans, according to health-care groups that have analyzed Medicare billing data. Federal officials investigating the allegedly fraudulent billing for catheters are looking into several of the companies that may be involved, according to three officials who spoke on the condition of anonymity to discuss the probe and three people who said the FBI approached them. The investigation’s existence has not been previously reported.
Over two years, one health-care group found, the companies collectively went from billing just 14 patients for catheters to nearly 406,000.
Urinary catheters made an appealing target for potential scammers because orders for the low-cost products — small tubes often made with latex or silicone — could escape some of the scrutiny that accompanies billing for expensive equipment, surgeries and other high-cost claims, fraud experts said.
The FBI’s public affairs office said it could not confirm or deny the existence of an investigation, citing the bureau’s standard practice. Officials at the Centers for Medicare and Medicaid Services also said they could not discuss the allegations, specific suppliers or the existence of a federal probe.